Response Rate and Outcomes in Crizotinib Treated Advanced ALK-Positive NSCLC Patients [POSTER ABSTRACT P1.01-P1.08]
Davis, K., Kaye, J., & Iyer, S. (2015). Response Rate and Outcomes in Crizotinib Treated Advanced ALK-Positive NSCLC Patients [POSTER ABSTRACT P1.01-P1.08]. Journal of Thoracic Oncology, 10(9, Suppl 2), S411-SS412. DOI: 10.1016/S1556-0864(16)30012-0
Crizotinib is an oral small-molecule tyrosine kinase inhibitor, which was approved in the United States (US) in August of 2011 for the treatment of anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). In clinical studies, crizotinib has demonstrated robust response rates and significantly greater efficacy than chemotherapy. However, there is currently limited data on crizotinib treatment and related outcomes in real-world practice settings. The main objective of the current study was to assess the treatment patterns and outcomes of ALK-positive advanced NSCLC patients treated with crizotinib in regular clinical practice.